Eur J Gastroenterol Hepatol 2022;34:567-575
When it comes to Retatrutide, the TRIUMPH Phase 3 program is evaluating it for chronic weight management, obstructive sleep apnea, knee osteoarthritis, and cardiovascular outcomes, with data continuing to emerge
It acts on GLP-1, GIP, and glucagon receptors, which makes it more comprehensive in its approach compared to Semaglutide, which focuses only on GLP-1
It is branded as a pre-workout, but
We have set up two pilot scale laboratories, which lay speedy and stable foundation for process amplification and production of superior products